SGMOQ · Sangamo Therapeutics, Inc
Market Cap
$66.29M
Shares
414.29M
SGMOQ metrics
59 of 114 screener metrics currently available.
Market overview
2 metricsShare price
$0.16
Market cap
$66.29M
Price action
19 metricsPrice change (1W)
+10.1%
Price change (30D)
+82.2%
Price change (3M)
-21.9%
Price change (6M)
-57.9%
Price change (YTD)
-61.0%
Price change (1Y)
-68.5%
Trailing year
Price change (5Y)
-98.4%
52-week high
$0.74
52-week low
$0.04
Change from 52-week high
-77.8%
Change from 52-week low
+310.0%
Annualized volatility
161.4%
Beta
2.1
RSI (14D)
63.8
Price vs SMA 50
+63.0%
Price vs SMA 200
-40.2%
Avg volume (3M)
4.80M
Relative volume
0.4
Average dollar volume
$483,828
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
414.29M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
1.9×
reciprocal yield 52.1%
P / book
—
FCF yield
-136.5%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-186.1%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2026-05-14
Profitability
9 metricsGross margin
—
Operating margin
-357.5%
Trailing 12 months
Net margin
-356.9%
Gross profit (TTM)
—
Operating profit (TTM)
−$123.56M
Net income (TTM)
−$123.33M
Trailing 12 months
Diluted EPS (TTM)
$-0.38
FCF margin
-261.8%
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
-77.6%
Year over year
Net income growth YoY
—
Revenue (TTM)
$34.56M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+76.9%
Year over year · more shares
Revenue CAGR (3Y)
-29.2%
Revenue CAGR (5Y)
-19.7%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
—
Return on assets
-205.7%
Debt / equity
—
Current ratio
0.7
EBITDA (TTM)
−$119.90M
Free cash flow (TTM)
−$90.46M
Quick ratio
0.7
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$27.59M
Total assets
$59.97M
Total debt
—
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$90.34M
Capital expenditures (TTM)
$115,000
R&D (TTM)
$113.23M
SG&A (TTM)
—
Stock compensation (TTM)
$7.47M
R&D / revenue
327.7%
Stock compensation / revenue
21.6%
Ownership (13F)
3 metrics13F filers
7
13F filer change QoQ
-107
Institutional ownership
0.3%
Short interest
3 metricsShort interest
2.4%
Latest settlement · 1.2 days to cover
Days to cover
1.2d
Short-squeeze score
58 / 100
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
—